Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
June 2026
in “
Dermatology and Therapy
”
Studysummary In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on link.springer.com →